Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.47 |
| ▸ | CCR2 | P41597 | 2/20 | 0.46 |
| ▸ | GUSB | P08236 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.41 |
| ▸ | USP5 | P45974 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21307056 | 0.86 | SCN9A (0.46) | HTR2CSCN9ACCR2GUSBHCRTR2 | |
| SCHEMBL21306627 | 0.86 | SCN9A (0.46) | HTR2CSCN9ACCR2GUSBHCRTR2 | |
| SCHEMBL21294772 | 0.85 | CCR2 (0.46) | HTR2CCCR2GUSBTAS1R3TAS1R1 | |
| SCHEMBL21294655 | 0.85 | HTR2C (0.48) | HTR2CCCR2GUSBTAS1R3TAS1R1 | |
| SCHEMBL21294786 | 0.84 | SCN9A (0.50) | HTR2CSCN9A | |
| SCHEMBL21294826 | 0.84 | SCN9A (0.55) | HTR2CSCN9ACCR2 | |
| SCHEMBL23140857 | 0.82 | HTR2C (0.49) | HTR2CSCN9ACCR2HCRTR2DRD2 | |
| SCHEMBL21294862 | 0.81 | SCN9A (0.51) | HTR2CSCN9ACCR2TAS1R3TAS1R1 | |
| SCHEMBL28495431 | 0.81 | SCN9A (0.44) | HTR2CSCN9AGUSB | |
| SCHEMBL20063536 | 0.81 | SCN9A (0.46) | HTR2CSCN9ACCR2HCRTR2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028075-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20190263786-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263786-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | ASAH2, ACER2, PCSK9 | HTR2C 2475/4885SCN9A 2136/4885CCR2 1546/4885 |
| US-11028075-B2 | Therapeutic compounds and methods of use thereof | TRPV1, HCN4, TRPA1 | HTR2C 823/4885SCN9A 90/4885CCR2 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.